StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research report released on Thursday morning. The brokerage issued a sell rating on the stock.
Separately, Cantor Fitzgerald reiterated an overweight rating and issued a $2.50 price target on shares of VolitionRx in a report on Wednesday, March 27th.
View Our Latest Research Report on VNRX
VolitionRx Stock Up 3.9 %
VolitionRx (NYSE:VNRX – Get Free Report) last posted its quarterly earnings data on Monday, March 25th. The company reported ($0.11) earnings per share (EPS) for the quarter. The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.50 million. Research analysts anticipate that VolitionRx will post -0.4 EPS for the current fiscal year.
Institutional Investors Weigh In On VolitionRx
An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new position in shares of VolitionRx Limited (NYSE:VNRX – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company’s stock.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
See Also
- Five stocks we like better than VolitionRx
- Why Invest in High-Yield Dividend Stocks?
- Comprehensive PepsiCo Stock Analysis
- Ride Out The Recession With These Dividend KingsĀ
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.